Tetratherix (ASX:TTX), a regenerative medicine company, has been highlighted by LSN Capital Partners. In May 2026, LSN described Tetratherix as a healthcare technology company that has developed a proprietary biomaterials platform designed to improve bone regeneration and surgical outcomes, with potential applications across orthopaedics, dental and soft tissue repair. Tetratherix operates in the Healthcare sector within the Biotechnology industry, and Thesis Tracker has captured 1 comment from 1 fund manager, LSN Capital Partners. Headquartered in Sydney, Tetratherix develops Tetramatrix, a biostealth fluid matrix technology that can be injected as a liquid and forms a scaffold in the body, supporting tissue regeneration and drug delivery, and is progressing clinical and regulatory pathways in Australia and the United States toward commercialisation, positioning it in the growing regenerative medicine market.